CIZ1B Lung Cancer Test

Cizzle Bio’s CIZ1B Lung Cancer Test Could Save Medicare $518 Million a Year While Improving Early Detection

Cizzle Bio shared a post on X:

“New ASCO2025 study: Cizzle Bio’s CIZ1B lung cancer test could save Medicare $518M/yr while improving early detection. 95% sensitivity for Stage I and 96% NPV = fewer procedures, earlier care. Study co-authored by Jennifer Hinkel.”

Read further.

More posts featuring Cizzle Bio.

ASCO2025 cancer CIZ1B CIZ1B lung cancer test Cizzle Bio Jennifer Hinkel Lung cancer Medicare OncoDaily Oncology